{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:09:22Z","timestamp":1787004562640,"version":"build-2736575974"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":172,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVE<\/jats:bold>\n                    Focus on long\u2010term side\u2010effects after cancer therapy in childhood has become of the utmost importance. The hypothalamic\u2010pituitary thyroid (HPT) axis is exposed to irradiation when some children are treated for acute lymphoblastic leukaemia (ALL) with prophylactic cranial irradiation (CIR). Whether this treatment causes hypofunction of the HPT axis remains controversal.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN<\/jats:bold>\n                    We measured plasma levels of total T3 (T3), total T4 (T4) and TSH before stimulation with TRH and plasma levels of TSH, 30 and 150\u2003minutes after stimulation with TRH in 95 patients in first continuous remission of childhood ALL.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PATIENTS<\/jats:bold>\n                    Patients diagnosed with ALL before the age of 15\u2003years between 1970 and 1991 and who were in first continuous remission and off treatment for at least one year were studied. The children were aged between 0\u00b75 and 14\u00b78\u2003years (median: 3\u00b79) at diagnosis of ALL. Thyroid function was assessed between 1\u00b72 and 18\u00b73\u2003years (median: 7\u00b76) after completion of therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS<\/jats:bold>\n                    We measured T4 levels before, and compared TSH levels before and after, stimulation with TRH in patients who were treated with prophylactic CIR (15\u201324\u2003Gy) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u200338) (CIR group) with patients who were treated with chemotherapy only (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u200357) (non\u2010CIR group).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS<\/jats:bold>\n                    We found that T3 and T4 levels were normal in all individuals (excluding the women who were on oral contraceptives). The median time from end of treatment to time at follow\u2010up was 9\u00b71\u2003years in the non\u2010CIR group\n                    <jats:italic>vs.<\/jats:italic>\n                    4\u00b72\u2003years in the CIR group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030\u00b7001), and the effect on follow\u2010up time was significant (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b704). It was estimated that just after irradiation, the TSH levels before and 30 and 150\u2003minutes after TRH stimulation was 49% lower in the CIR group; however, after 4\u00b70\u2003years, TSH levels were not significantly different between the two groups. Although within normal limits, the T4 levels were significantly higher in the CIR group compared to the non\u2010CIR group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b7003). It was estimated that, just after the end of treatment, T4 was 19\u00b79% higher in the CIR group. However, in the CIR group, the T4 level decreased significantly over time with \u22121\u00b75% per year (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b7025), while the difference in the non\u2010CIR group was not significant. There was no correlation between T4 and TSH levels and sex, age at diagnosis, age at the end of treatment or age at follow\u2010up.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSIONS<\/jats:bold>\n                    We conclude that, in our cohort of survivors of childhood ALL, prophylactic cranial irradiation of the central nervous system did not have an adverse effect on hypothalamo\u2010pituitary\u2010thyroid function within a median follow\u2010up time of 8\u2003years.\n                  <\/jats:p>","DOI":"10.1046\/j.1365-2265.2001.01292.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T05:50:08Z","timestamp":1047361808000},"page":"21-25","source":"Crossref","is-referenced-by-count":36,"title":["Thyroid function in survivors of childhood acute lymphoblastic leukaemia: the significance of prophylactic cranial irradiation"],"prefix":"10.1111","volume":"55","author":[{"given":"Ane","family":"Lando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se Krogh","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt\u2010Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Holm","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Practical Statistics For Medical Research.","author":"Altman D.G.","year":"1991"},{"key":"e_1_2_6_3_1","first-page":"489","article-title":"Testing for thyroid function recovery in children and adolescent with Hashimoto thyroiditis","volume":"24","author":"Battelino T.","year":"1994","journal-title":"Annals of Clinical and Laboratory Science"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019409141900"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.64.4.631"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199105000-00008"},{"key":"e_1_2_6_7_1","first-page":"581","article-title":"Endocrinologic function following cranial irradiation in acute lymphoblastic leukemia in childhood","volume":"103","author":"Lackner H.","year":"1991","journal-title":"Wiener Klinische Wochenschrift"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346906"},{"key":"e_1_2_6_9_1","volume-title":"Treatment of ALL, NOPHO Protocol 1986.","author":"Nordic Society of Pediatric Hematology and Oncology","year":"1986"},{"key":"e_1_2_6_10_1","first-page":"375","article-title":"Subtle primary hypothyroidism in patients treated for acute lymphoblastic leukemia","volume":"124","author":"Pasqualini T.","year":"1991","journal-title":"Acta Endocrinologica (Copenhagen)"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-6-1750"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.12.4472"},{"key":"e_1_2_6_13_1","volume-title":"SAS\/STAT User's Guide: Statistics, Version 6","author":"SAS Institute Inc.","year":"1990"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-39-3-595"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.64.11.1635"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00222-3"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1977.tb02022.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860401)57:7<1287::AID-CNCR2820570706>3.0.CO;2-O"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2001.01292.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2001.01292.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.2001.01292.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T04:51:26Z","timestamp":1697518286000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.2001.01292.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1046\/j.1365-2265.2001.01292.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01292.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}